# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Three New Sites Join HT-001 Trial, GW University Hospital, UC Irvine and Northwell Health
Nvidia BioNeMo generative AI platform will be used to accelerate the training of models on proprietary dataNEW YORK, June 10, 2...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Hoth Therapeutics (NASDAQ:HOTH) with a Buy and maintains $4 pr...
EF Hutton analyst Tim Moore maintains Hoth Therapeutics (NASDAQ:HOTH) with a Buy and raises the price target from $6.5 to $7.